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Sltlmlilary 
Adherence of Plasmodium fakiparum-infected  erythrocytes to cerebral  postcapillary venular en- 
dothelium is believed to be a critical step in the development of cerebral  malaria. Some of the 
possible receptors mediating adherence have been identified, but the process of adherence in vivo 
is poorly understood. We investigated the role of carbohydrate ligands in adherence,  and we 
identified chondroitin sulfate (CS) as a specific receptor for P. falciparum-infected  erythrocytes. 
Parasitized cells bound to Chinese hamster ovary (CHO) cells and C32 melanoma cells in a chon- 
droitin sulfate-dependent manner, whereas glycosylation mutants lacking chondroitin sulfate 
A (CSA) supported little or no binding. Chondroitinase treatment of wild-type CHO cells re- 
duced binding by up to 90%. Soluble CSA inhibited binding to CHO cells by 99.2  _+  0.2% 
at 10 mg/ml and by 72.5  _+  3.8%  at 1 mg/ml, whereas a range of other glycosaminoglycans 
such as heparan sulfate had no effect. Parasite lines selected for increased binding to CHO cells 
and most patient isolates bound specifically to immobilized CSA. We conclude that P. falciparum 
can express  or expose  proteins at the surface of the infected erythrocyte that mediate specific 
binding to CSA. This mechanism of adherence may contribute to the pathogenesis of P. J~l- 
ciparum malaria, but has wider implications as an example of an infectious agent with the ca- 
pacity to bind specifically to cell-associated  or immobilized CS. 
C 
Ytoadherence of Plasmodium falciparum-infected erythro- 
cytes (IEs) 1 to cerebral  postcapillary venular endothe- 
lium is a striking feature of the pathology of cerebral malaria 
(1, 2). The phenomenon has been studied in vitro using cell 
lines such as human endothelial cells (3,  4) and C32 mela- 
noma cells (5), and a variety of purified glycoprotein receptors. 
Thrombospondin (6), CD36 (7), intercellular adhesion mol- 
ecule 1 (ICAM-1) (8), vascular cell adhesion molecule 1, and 
E-selectin (9) have all been implicated as receptors on host 
cells, but the adherence patterns observed in some studies 
(4, 10, 11) suggest that additional, as yet unidentified, receptors 
exist. Sulfated glycoconjugates, including the glycosamino- 
glycan (GAG) heparin, interfere with attachment of Plasmo- 
dium sporozoites to the hepatocyte surface and may decrease 
sporozoite infectivity in mice (12, 13). 
We tested the hypothesis that GAGs may be involved in 
cell-cell interactions in asexual stages of P.fakiparum and found 
that IEs bound to cell-associated chondroitin sulfate (CS) and 
to immobilized chondroitin sulfate A (CSA) and that binding 
was inhibited by hydrolysis of cell surface CS, or by free CSA. 
1 Abbreviations  used in thispaper: CHO, Chinese  hamster ovary;  CS, chon- 
droitin sulfate; CSA, CSB, and CSC, chondroitin  sulfates  A, B, and C, 
respectively; GAG, glycosaminoglycan;  HS, heparan sulfate; HUVEC, 
human umbilical  vein  endothelial  cell; ICAM-1, intercellular  adhesion  mol- 
ecule 1; IE, infected  erythrocyte;  PE, dipalmitoylphosphatidylethanola- 
mine; TM, thrombomodulin. 
Materials and Methods 
Chemicals.  Heparin (porcine intestinal mucosa), heparan sul- 
fate (HS) (bovine kidney), dextran sulfate, fucoidan, CSA (porcine 
rib cartilage), chondroitin sulfate  B (CSB) (bovine  mucosa), chon- 
droitin sulfate  C (CSC) (shark cartilage), chondroitinase  ABC (from 
Proteus vulgaris), heparitinase (from  Flavobacterium heparinum), 
chymotrypsin, and pronase  were from Sigma Chemical  Co. (Sydney, 
Australia), and t-l-tosylamido-2-phenylchloromethyl  ketone-treated 
trypsin (trypsin-TPCK)  was from Worthington Biochemical  Corp. 
(Freehold, NJ). 
ParasitizedErythrocytes.  Parasite  strains FAF-EAS, D7, and El0 
were derived  from the Brazilian  isolate  ItG2F6. FAF-EA8  was cloned 
and selected on endothelial cells (10, 14), and D7 and El0 were 
cloned and selected for rosetting. FAF-EASCHO5  was selected  five 
times on Chinese hamster ovary (CHO) cells and D7CHO6 and 
E10CHO6 were selected six times, as will be described. Primary 
isolates A-F were from children living in Madang, Papua New 
Guinea (provided by Dr. F. A1-Yaman, Papua New Guinea Insti- 
tute of Medical Research). Primary isolates G-I were from Aus- 
tralian travellers who had acquired malaria in various countries. 
Parasites were cultured as previously described (15), but using 5% 
human serum. Cultures were synchronized every 1-2 wk by sor- 
bitol lysis (16). 
Cell Lines.  Wild-type (K1) CHO cells and CHO cell glycosy- 
lation mutants (gifts of Prof. Jeffrey D. Esko, University of Ala- 
bama at Birmingham, Birmingham, AL) and C32 amelanotic  mela- 
noma cells (AT'IC CtLL 1585; American Type Culture Collection, 
KockviUe, MD) were cultured and plated as described (3, 5, 17). 
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expresses no HS, with a compensatory increase in CS, and mutant 
745  expresses neither HS nor CS (18). 
Purified Ligands.  Platelet-derived CD36  (7)  (Dr.  M.  Berudt, 
Baker Institute, Melbourne, Australia) was used at 1 #g/ml, and 
recombinant soluble ICAM-1 (Dr. A. Boyd, The Walter and Eliza 
Hall Institute of Medical Research, Melbourne, Australia)  was used 
at 10 #g/ml. Duplicate spots of CD36 or ICAM-1 (40 #1 for labo- 
ratory strains;  10 #1 for wild-type isolates) were adsorbed overnight 
onto 36-mm petri dishes, blocked with 1% BSA, and washed with 
RPMI-Hepes (MultiCel; Cytosystems, Castle Hill, Australia) be- 
fore assays. 
Cytoadherence Assays, Inhibition of  Binding by GAGs, and Erythro- 
cyte Rosette Formation.  Assays were performed at 3-7% parasitemia 
and 2% hematocrit in RPMI-Hepes supplemented with 10% serum. 
IEs were incubated with purified ligands or cells for 1 h at 37~ 
before nonadherent cells were washed off with RPMI-Hepes. To 
assess binding, dishes were fixed with 2% glutaraldehyde, stained 
with Giemsa, and examined microscopically. At least 300 CHO 
cells or 500 adherent IEs were counted. GAGs and other glycocon- 
jugates were tested for inhibition of binding by adding them to 
the parasite culture (at a final concentration of 10 #g/ml) immedi- 
ately before the assay. Rosetting assays were performed as previ- 
ously described (19). 
Selection  for Increased CHO Cell Binding.  To select for increased 
CHO cell binding, after removal of nonadherent cells in the assay 
described,  the  adherent  cells  were incubated with  fresh culture 
medium and erythrocytes. The next day, after trophozoite matura- 
tion, division, and reinvasion, ring IEs were transferred to a new 
dish. To prevent the introduction of viable CHO cells into the on- 
going culture, CHO cells were irradiated (3,000 rads) immediately 
before use. 
Enzyme Treatment of CHO Cells and of  lEs.  K1 CHO cells were 
incubated with chondroitinase ABC (which cleaves linkages in CSA, 
CSK and CSC) or heparitinase  (which specifically cleaves HS chains) 
in RPMI-Hepes for 45 rain at 37~  and then washed three times 
with RPMI-Hepes. For protease treatment of erythrocytes,  the FAF- 
EA8CHO5 culture was washed once in RPMI-Hepes and suspended 
at 3% hematocrit in 100 #g/ml protease at 37~  for 30 min. The 
reaction was quenched with  10% human serum, and cells were 
washed three times with PBS before the binding assay. 
GAG Conjugates.  CSA and heparin were linked to dipalmitoyl- 
phosphatidylethanolamine  (PE)  through  the reducing terminus, 
using the method of Sugiura et al. (20). Concentration of PE-linked 
material was determined by hexuronic acid assay. PE-linked CSA 
(CSA-PE) was used at a concentration of 50 #g/ml, and heparin- 
PE was used at 260 #g/m1. Duplicate 25-#1 spots (10 #1 for pri- 
mary isohtes) were adsorbed onto petri dishes overnight and blocked 
for 30 min with 1% BSA. Adherence assays were performed and 
counted as previously described. For prevention of adherence, CSA 
or HS was added to parasitized cells at 10 #g/m1 immediately be- 
fore the assay. 
Results 
Selection for Binding to ClIO Cells Selects  for Binding to CS 
and Alters Adherence to Other Ligands.  The three parasite lines 
were selected for increased binding  to CHO  cells.  CS nor- 
mally forms "~30%o of GAG on the cell surface. Binding of 
the selected line FAF-EA8CHO5 was completely dependent 
on the presence of cell surface CS.  IEs bound well to CHO 
cell mutant 677, which expressed excess CS and no HS, but 
adhesion to 745 CHO  cells (with neither HS nor CS) was 
absent (Table 1). The binding of the selected lines D7CHO6 
and E10CHO6 was mainly, but not completely, attributable 
to  CS  (Table  1). 
Selection for binding to CHO  cells altered the adherence 
profile to other ligands.  Binding to ICAM-1 and CD36 de- 
creased markedly, by >95% for parasite line FAF-EA8 (Table 
1). Adherence to C32 melanoma cells increased and became 
more readily inhibited  by CSA  (Table  1),  in keeping with 
the observation that between 2 and 11 CS chains are attached 
to a  250-kD  surface proteoglycan  of melanoma cells  (21). 
Free CSA Inhibits and Reverses Binding to ClIO Cells.  The 
CSA used (from porcine rib cartilage) is composed of pre- 
dominantly  4-sulfated N-acetylgalactosamine  and  approxi- 
mately equal amounts of glucuronic  acid and iduronic  acid 
(22). CSA significantly impaired binding of FAF-EA8CHO5 
Table  1.  Binding of Infected Erythrocytes to Cells and Purified Ligands 
Cells and purified ligands  tested 
C32 + CSA binding 
Line  K1  CHO  677 CHO  745 CHO  HUVEC  C32  (inhibition  %)  CD36  ICAM-1 
FAF-EA8  82  _+  12  ND  ND  692  _+  60  1,133  _+  37  968  +  45  (14.6%)  1,253  +  262  642  _+  106 
FAF-EA8 
CHO5  2  +  1 
El0  ND 
E10CHO6  149  +  9 
D7  ND 
D7CHO6  84  _+  8 
585  +  29  2,215  +  491  17_+  9  2,149_+  362  80-+  25  (96.3%)  59  +  9  6  +  2 
13  +  2  ND  221  _+  63  227  _+  15  176  +  48  (22.5%)  ND  184  _+ 41 
430  +  36  1,344  _+  193  53  -+ 6  1,285  +  33  370  + 77 (71.2%)  324  _+  80  100  +  11 
40  +  8  ND  665  +  112  559  +  88  466  +  96  (16.6%)  501  +  95  76  +  6 
635  +  91  1,740  +  344  220  + 39  1,605  -+  159  671  _+  147  (58.2%)  142  +  16  73  +  18 
Comparison of selected lines and parent lines for adherence to wild-type CHO cells, CHO glycosylation mutants 677 and 745, CD36,  ICAM-1, 
human umbilical vein epithelial cells (HUVECs),  and C32. Values are mean  +  SE binding for triplicate experiments. Binding to cells is per 100 
cells; binding  to purified ligands is per square millimeter. 
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Figure 1.  Inhibition of binding of FAF-EA8CHO5 to K1 CHO cells 
by GAGs and glycoconjugates.  All chemicals were added to binding assays 
at 10 ~g/ml; CSA was additionally used at 1/~g/ml. Results show binding 
as a percentage of control, with mean  _  SE for triplicate experiments. 
to K1 CHO cells at 10/~g/ml (99.2  _+ 0.2%) and 1/~g/ml 
(72.5  _+ 3.8%). CSB contains "~85% iduronic acid, and CSC 
consists of 6-sulfated N-acetylgalactosamine and glucuronic 
acid.  Neither inhibited binding  at  10/xg/ml  (Fig.  1).  HS, 
the predominant  CHO  cell surface GAG,  did not inhibit 
binding, even at 100/~g/ml. Free CSA had no effect on binding 
to ICAM-1 or CD36 (data not shown). Addition of free CSA 
at time points during an adherence assay substantially reversed 
cytoadherence. Free CSA (10/~g/ml)  added  15 min before 
completion of a binding assay released >80% of bound para- 
sites  (data not  shown). 
Treatment of CliO Cells with Chondroitinase or IEs with Pro- 
tease but Not Trypsin Reduces Cytoadherence.  Treatment  of 
CHO  cells  with  chondroitinase  ABC  markedly  reduced 
binding, but heparitinase  had no effect (Fig.  2). Treatment 
of IEs with chondroitinase or heparitimse did not alter binding 
(data not shown). Trypsin treatment of the IEs had no effect 
on binding to CHO cells, whereas both chymotrypsin and 
pronase reduced adherence (Fig. 2), suggesting that a trypsin- 
resistant protein mediates adherence to CSA on CHO ceils. 
Binding to Immobilized CSA.  CSA and heparin were con- 
jugated to PE to allow immobilization of GAG on polysty- 
rene plates. Parental strains bound to CSA-PE, and binding 
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Figure 2.  Effect of glycosidase  treatment of CHO cells and protease 
treatment of IEs on cytoadherence.  Results show the percent decrease in 
binding (_+SE) compared with control for triplicate experiments. 
was increased in selected lines (Table 2), but there was no 
significant binding to heparin-PE.  Binding was almost to- 
tally inhibited by free CSA, but HS had no effect (Table 2). 
Patient Isolates  May Bind to Immobilized CSA.  Five of nine 
primary isolates tested bound to CSA-PE (Table 3), suggesting 
that this phenomenon is likely to be of biological relevance 
in natural infections. The isolates were also examined for ro- 
sette formation and for binding to CD36, ICAM-1, and CSA. 
All formed rosettes and adhered to CD36, and six adhered 
to ICAM-1 at >5/mm ~ (Table 3). In this small study, there 
was no correlation between CSA binding and other pheno- 
typic characteristics.  Although levels of CSA binding were 
modest, isolate F was successfully adapted to in vitro culture 
and then underwent three rounds of selection on CSA-PE. 
This selected line bound very well to CSA-PE (>2,000 IEs 
per mme). 
Discussion 
Several infectious agents are known to adhere to HS (23-25), 
and proteoglycans containing HS are widely distributed on 
vascular endothelium (26). The intravascular distribution of 
CS proteoglycans has not been well studied, and to our knowl- 
edge, binding of infectious agents to CS has not been previ- 
ously described. 
Variation in expression of CS on endothelia in sites of para- 
site sequestration  could represent a host factor in malaria patho- 
Table  2.  Binding of Infected Erythrocytes to Immobilized Glycosaminoglycans 
Line  CSA-PE  Heparin-PE  CSA-PE  +  CSA  CSA-PE  +  HS 
FAF-EA8  90  _+  9  0.5  +  0.2  0.8  _+  0.3  105  +_  9 
FAF-EA8CHO5  2,350  _+  269  7  +  4  0.25  +_  0.2  2,488  _+  143 
El0  32  _+ 6  0.5  +  0.2  0.7  +  0.4  39  _+ 7 
E10CHO6  987  +  108  0.7  _+ 0.5  0.7  _+ 0.5  1,033  _+ 83 
D7  36  +  8  0.5  +  0.2  0.1  _+ 0.1  ND 
D7CHO6  3,400  _+  187  0  +  0  0.9  _+ 0.5  3,091  _+  199 
Adherence of IEs to CSA-PE or heparin-PE and to CSA-PE in the presence of flee CSA or HS (10 #g/ml).  Results are expressed as parasites 
bound per mm  2 and show mean  _+  SE for triplicate experiments. 
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Isolate  Parasitemia  Rosetting  CD36  ICAM-1  CSA-PE 
A  1.0%  1% 
B  0.9%  0.7% 
C  1.3%  1.7% 
D  0.7%  4.5% 
E  1.6%  1.7% 
F  13.0%  7.5% 
G  11.2%  5.9% 
H  3.8%  15% 
I  2.2%  1.7% 
69, 93 
334  337 
335  347 
288  309 
541  192 
3780. ND 
3540. 2995 
2385  2267 
469  524 
54, 36  0,  0, 0,  1 
4, 4  12,  10,  12,  12 
3,5  0,1,4,1 
2,2  2,1,0,0 
37,  16  8, 5, 6,  13 
83, 122  55, 50, 32, 82 
21, 44  8,  8, 23, 6 
327, 255  8,  24, 27 
16,  14  0,  1, 0, 0 
patient isolates were tested for rosette formation and for binding to CD36, ICAM-1, and CSA-PE. Binding is expressed as parasites bound per 
square millimeter  for duplicate  assays  (each  of two spots for CSA-PE), and rosetting is given  as the percentage  of trophozoite-IEs  in rosettes. Parasite- 
mias represent the percentage of all erythrocytes  infected with trophozoites at the time of assay. 
genesis. One or more CS chains can be linked to thrombomod- 
ulin (TM)  (27),  an integral membrane protein of vascular 
endothelium. These chains, composed predominantly of CSA, 
have functional activity in thrombin-TM interactions. CS may 
also be attached to the endothelial proteoglycan ryudocan in 
the rat (28). We speculate that CSA attached to TM, or poten- 
tially to human ryudocan, may be involved in adhesion in 
vivo. Our preliminary data (Rogerson, S. J., unpublished ob- 
servations)  show that HUVECs from some but not all in- 
dividual donors have detectable surface CSA. This agrees with 
the observations ofLin et al. (29) that HUVECs from pooled 
donors contain less TM, and a lower proportion of TM that 
has CS attached, than arterial endothelial cells from a single 
donor. The expression of other receptors that mediate adher- 
ence of IEs to endothelium has recently been shown to correlate 
with patterns of sequestration (30), but the distribution of 
CSA on microvascular endothelium representing preferred 
sites of sequestration was not examined by Lin et al. (29). 
We have recently described trypsin-resistant adherence to 
C32 melanoma cells of a parasite line, T4, that has a trypsin- 
resistant, chyomotrypsin-sensitive, high molecular weight pro- 
tein detectable by surface radioiodination (10). Binding of 
T4 to C32 melanoma cells was reduced by free CSA (Chaiyaroj, 
S. C., unpublished observations).  As with the CHO-selected 
lines, T4 binds less effectively than the parent FAF-EA8  to 
CD36 and ICAM-1. We postulated that this trypsin-resistant 
ligand on IEs mediates adherence (10), and we now believe 
that it may be interacting with CSA as receptor on the mela- 
noma cell surface. It is unclear whether this represents a variant 
form of the putative cytoadherence molecule P. fakiparurn 
erythrocyte membrane protein 1 (31), but multiple ligands 
on the IEs are thought to mediate endothelial cell adherence 
in vitro (32),  and more than one may be expressed  simul- 
taneously (10). 
Our finding that primary isolates  and laboratory strains 
of P. falciparum  adhere to CSA may explain the previously 
observed  adherence of parasite line FC27 to an unidentified 
ligand on microvascular  endothelial cells (4), and it is consis- 
tent with the observations of Hasler et al. (11) that one of 
five Malawian isolates bound at significant levels to wild-type 
CHO cells. These data suggest that ICAM-1 and CD36 trans- 
fected CHO cells (11) may not be appropriate substitutes for 
the immobilized ligands in assessing adherence,  as the con- 
tribution of CSA binding cannot readily be determined. Al- 
though binding of primary isolates was modest, in vitro se- 
lection  increased  this  binding,  and  similar  sdection  for 
adherence  to CSA may operate in vivo. 
The marked difference in inhibition of binding by CSA 
compared with CSB or CSC was surprising. The sulfation 
pattern and the proportions of glucuronic acid and its epimer 
iduronic acid in CS chains may be very variable  (22).  The 
porcine  rib  cartilage  CSA  used  contains  predominantly 
4-sulfated  N-acetylgalactosamine and approximately equal 
amounts of glucuronic acid and iduronic acid (22), whereas 
CSB  contains  a  low  proportion  of glucuronic  acid,  and 
N-acetylgalactosamine residues  in CSC are predominantly 
6-sulfated. Although the current study did not elucidate the 
specific oligosaccharide motif that supports binding to the 
ligand on IEs, it appears to involve structures present in CSA 
that occur infrequently in the CSB or CSC preparations used. 
The relative involvement of glucuronic acid and iduronic acid 
in such a motif can be clarified only by studies  using well- 
defined oligosaccharides. 
The novel finding that CSA may act as a specific receptor 
for an infectious agent is of general interest, expanding the 
established  roles of GAGs in cell-cell interactions. The dis- 
covery that CSA can be an adherence ligand for asexual stages 
of P. falciparum adds an extra level of complexity to attempts 
to unravel the interplay of IEs and host adhesion molecules 
and their relevance to the pathogenesis of severe malaria. These 
data suggest that malarial cytoadherence, like leukocyte adhe- 
sion, may involve both glycoprotein and carbohydrate receptors 
and offer a new approach to investigate the relationship be- 
tween adherence and disease severity that has proved so elusive. 
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